Lupus

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-…

Early in medical training, we are taught diagnoses are made 90% of the time based only on the history and physical exam of the patient; laboratory tests play a minor role. When ordered, tests are…

For lupus, sedentary lifestyle may be a driving force of disease activity.  Today, the final day of ACR, Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical…

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty…

Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now.   In Abstract #0939, Dr. J Patricia…

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…

Women with systemic lupus erythematosus (SLE) face unique reproductive challenges including increased risk of thrombosis with estrogen-containing contraceptives, preeclampsia, pregnancy loss, and…

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition and monitoring disease activity is an important aspect of disease management.  The anti-dsDNA antibody is highly specific for…

Recently the FDA approved deucravacitinib (DEUC), a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in systemic lupus erythematosus.…

ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick…